Clinical Research

Regenexx has been at the forefront of interventional orthobiologics, conducting extensive research to demonstrate the efficacy and safety of its procedures. The organization boasts a comprehensive collection of peer-reviewed published studies, clinical trials, and a robust research team dedicated to advancing the field of interventional orthobiologics.

Clinical Studies

Regenexx conducts ongoing clinical trials to refine our methodologies and explore new applications. These studies are crucial for demonstrating the long-term benefits and safety of our treatments. Current studies include investigations into the effectiveness of platelet-based treatments for lumbar degenerative disc disease and other musculoskeletal conditions.

Research Team

The Regenexx research team is composed of leading scientists and clinicians specializing in interventional orthobiologics. Notable team members include:

Matt Murphy, PhD, VP of R&D and Clinical Affairs

Matt Murphy, PhD, VP of R&D and Clinical Affairs, has extensive experience in biomaterials for orthopedic tissue engineering.

Ehren Dodson, Clinical Research Director

Ehren Dodson, PhD, Clinical Research Director, is responsible for coordinating clinical trials and advancing the clinical applications of regenerative therapies.

Dustin Berger, MS-Senior Research Scientist

Dustin Berger, Senior Research Scientist, focused on the osteogenic potential of stem cells and interventional orthopedic treatments.

Peer-Reviewed Publications

Regenexx has published numerous studies in high-impact journals, focusing on various applications of interventional orthobiologics. Key publications include:

  • A randomized controlled trial comparing percutaneous bone marrow concentrate (BMC) and platelet products to exercise therapy for rotator cuff tears, demonstrating significant improvements in function and pain reduction over two years. View report.
  • Research on the use of percutaneous autologous BMC for knee osteoarthritis, highlighting positive patient-reported outcomes and the therapeutic potential of progenitor cell content. View report.
Filter by topic:
Filter by year: